A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS)

PHASE2UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 27, 2017

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
ALSAmyotrophic Lateral Sclerosis
Interventions
DRUG

Pimozide 2mg/day (current) or 4 mg/day (study initiation)

Pimozide 2mg tablets will be taken once daily.

DRUG

Placebo Oral Tablet

Identical matching placebo lactose tablets

Trial Locations (9)

T3M 1M4

RECRUITING

Dr. Lawrence Korngut -South Health Campus, Calgary

T6G2G3

RECRUITING

Dr. Wendy Johnston - University of Alberta, Edmonton

E3B 0C7

RECRUITING

Dr. Colleen O'Connell - Stan Cassidy Centre for Rehabilitation, Fredericton

L8N 3Z5

RECRUITING

Dr. John Turnbull McMaster University/Hamilton Health Services, Hamilton

N6A5A5

RECRUITING

Dr. Christen Shoesmith - London Health Sciences Centre, London

K1Y4E9

RECRUITING

Dr. Ariel Breiner -Ottawa Hospital Research Institute, Ottawa

M4N 3M5

RECRUITING

Dr. Lorne Zinman Sunnybrook Research Institute, Toronto

J4V 2J2

RECRUITING

Dr. Sandrine Larue - Reserche Sepmus Inc., Greenfield Park

H2L4M1

RECRUITING

Dr. Genevieve Matte, Montreal

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

ALS Canada

UNKNOWN

collaborator

Brain Canada

OTHER

lead

University of Calgary

OTHER